References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-194-10-138-146

nogr-1770

Research Article

ОБЗОР

REVIEW

Воспалительные заболевания кишечника и лекарственно индуцированное поражение печени

Inflammatory bowel disease and drug-induced liver damage

https://orcid.org/0000-0002-5413-9599

Волынец

Г. В.

Volynets

G. V.

Волынец Галина Васильевна - доктор медицинских наук, главный научный сотрудник, руководитель отдела гастроэнтерологии Научно-исследовательского клинического института педиатрии им. академика Ю.Е. Вельтищева.

125412, Москва, улица Талдомская, дом 2.

Galina V. Volynets - MD, PhD, Dr. Sci, chief researcher of the Department of Gastroenterology of the Veltischev Research and Clinical Institute for Pediatrics.

125412, Moscow, Taldomskaya street, 2.

volynec_g@mail.ru

https://orcid.org/0000-0001-7308-7280

Хавкин

А. И.

Khavkin

A. I.

Хавкин Анатолий Ильич - доктор медицинских наук, профессор, главный научный сотрудник Научно-исследовательского клинического института педиатрии имени академика Ю.Е. Вельтищева.

125412, Москва, улица Талдомская, дом 2.

Anatoly I. Khavkin - MD, PhD, Dr. Sci, Professor, chief researcher of the Veltischev Research and Clinical Institute for Pediatrics.

125412, Moscow, Taldomskaya street, 2.

РНИМУ им. Н.И. Пирогова Минздрава РФРоссияPirogov Russian National Research Medical UniversityRussian Federation

2021

23122021

010138146

2021

Волынец Г.В., Хавкин А.И.

Volynets G.V., Khavkin A.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/1770

В статье представлены результаты обзора публикаций, посвящённых изучению проблем лекарственно индуцированных поражений печени при воспалительных заболеваниях кишечника (ВЗК). Рассматривается гепатотоксическое действие тиопуринов, (азатиоприн и 6-меркаптопурин), гепатоттоксичность которых регистрируется от 0% до 17%; сульфасалазина и месаламина (гепатотоксичность от 0% до 4%); метотрексата (гепатотоксичность от 15% до 50%), ингибиторов фактора некроза опухоли (гепатотоксичность до 75% случаев), анти-интегринов (гепатотоксичность от 2% до 5%); ингибитора интерлейкинов 12/23 (гепатотоксичность от 0,5% до 2%); ингибиторов янус-киназ (гепатотоксичность от 1% до 2%).

Вывод. Лекарственные препараты, используемые в настоящее время для лечения ВЗК, требуют периодической оценки функциональных проб печени для исключения лекарственно индуцированных поражений, требующих коррекции терапии. Поскольку круг новых лекарственных препаратов быстро расширяется, это требуют особого наблюдения и обсуждения в плане их неблагоприятного действия на печень.

The article presents the results of a review of publications devoted to the study of the problems of drug-induced liver damage in inflammatory bowel diseases (IBD). The hepatotoxic effect of thiopurines (azathioprine and 6-mercaptopurine) — hepatotoxicity from 0% to 17%; sulfasalazine and mesalamine (hepatotoxicity from 0% to 4%); methotrexate (hepatotoxicity from 15% to 50%); tumor necrosis factor inhibitors (hepatotoxicity up to 75% of cases.), anti-integrins (hepatotoxicity from 2% to 5%); an interleukin 12/23 inhibitor (hepatotoxicity from 0,5% to 2%); Janus-kinase inhibitors is considered (hepatotoxicity from 1% to 2%).

Conclusion. The drugs currently used to treat IBD require periodic liver function tests to rule out drug-induced lesions that require therapy correction. As the range of new drugs is rapidly expanding, this requires special observation and discussion in terms of their adverse effects on the liver.

воспалительные заболевания кишечникалекарственно индуцированное поражение печени

inflammatory bowel diseasedrug-induced liver damage

References1

Волынец Г. В. Семейный внутрипечёночный холестаз: проблемы и перспективы. Российский педиатрический журнал. 2019; 22(6): 388-394. DOI: 10.18821/1560-9561-2019-22-6-388-394

Volynets G. V. Familial intrahepatic cholestasis: problems and prospects. Russian Pediatric Journal. 2019; 22 (6): 388-394. (in Russ.) DOI: 10.18821/1560-9561-201922-6-388-394

Волынец Г. В., Никитин А. В. Холестатические болезни у детей: монография. - М.: ООО «ОППОНЕНТ», 2020. - С. 52-57. ISBN 978-5-6043659-0-8.

Volynets G.V., Nikitin A. V. Cholestatic diseases in children: monograph. Moscow. LLC “OPPONENT” Publ, 2020. pp.52-57. (in Russ.) ISBN 978-5-6043659-0-8.

Andrade R.J., Chalasani N., Bjornsson E. S., Suzuki A., Kullak-Ublick G.A., Watkins P. B., et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019; 5(1):58. PMID: 31439850. DOI: 10.1038/s41572-019-0105-0.

Yaccob A., Mari A.. Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease. Frontline Gastroenterology. 2019; 10(3):309-15. PMID: 31281626. DOI: 10.1136/flgastro-2018-101037.

Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Epub 2008 May 28. PMID: 18506437.

Wong D.R., Coenen M. J., Derijks L. J., Vermeulen S. H., van Marrewijk C. J., Klungel O. H., et al.; TOPIC Recruitment Team. Aliment Pharmacol Ther. 2017;-45(3):391-402. PMID: 27943397. DOI: 10.1111/apt.13879.

Marinaki A., Arenas-Hernandez M.. Reducing risk in thiopurine therapy. Xenobiotica. 2020; 50(1):101-9. PMID: 31682552. DOI: 10.1080/00498254.2019.1688424.

Dong X., Zheng Q., Zhu M., Tong J. L., Ran Z. H. Thiopurine Smethyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol. 2010; 16(25):3187-95. PMCID: PMC2896757. DOI: 10.3748/wjg.v16.i25.3187.

Gisbert J.P., Gonzalez-Lama Y., Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007; 102: 1518-1527. PMID: 17391318 DOI: 10.1111/j.1572-0241.2007.01187.x.

Chaparro M., Ordas I., Cabre E., Garcia-Sanchez V., Bastida G., Penalva M., et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Infl amm Bowel Dis. 2013;19(7):1404-10. PMID: 23665964. DOI: 10.1097/MIB.0b013e318281f28f.

Schroder T., Schmidt K. J., Olsen V., Moller S., Mackenroth T., Sina C., et al. Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment. Eur J Gastroenterol Hepatol. 2015; 27: 698-704. PMID: 25923946. DOI: 10.1097/MEG.0000000000000350

Romagnuolo J., Sadowski D. C., Lalor E., Jewell L., Thomson A. B. Cholestatic hepatocellular injury with Azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol. 1998; 12: 479-483. PMID: 9812167. DOI: 10.1155/1998/294752.

Seinen M.L., van Asseldonk D. P., de Boer N. K., Bouma G., van Nieuwkerk C. M., Mulder C. J., et al. Nodular regenerative hyperplasia of the liver in patients with IBD treated with allopurinolthiopurine combination therapy. Inflamm Bowel Dis. 2017;23(3):448-52. PMID: 28151736. DOI: 10.1097/MIB.0000000000001036.

Gisbert J.P., Luna M., Gonzalez-Lama Y., Pousa I. D., Velasco M., Moreno-Otero R., et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007; 13: 1106-1114. PMID: 17455203. DOI: 10.1002/ibd.20160.

Shaye O.A., Yadegari M., Abreu M. T., Poordad F., Simon K., Martin P., et al. Hepatotoxicity of 6-mercapto-purine (6-МП) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007; 102: 2488-2494. PMID: 17764490. DOI: 10.1111/j.1572-0241.2007.01515.x.

Hindorf U., Johansson M., Eriksson A., Kvifors E, Almer S. H. Mercaptopurine treatment should be considered in Azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Th er. 2009; 29: 654-661. PMID: 19183142. DOI: 10.1111/j.1365-2036.2008.03925.x.

Meijer B., Seinen M. L., van Egmond R., Bouma G., Mulder C. J.J., van Bodegraven A. A., et al. Optimizing thiopurine therapy in inflammatory bowel disease among 2 real-life intercept cohorts: effect of allopurinol comedication. Inflamm Bowel Dis. 2017;23(11):2011-7. PMID: 28617756. DOI: 10.1097/MIB.0000000000001168.

Kreijne J.E., de Veer R. C., de Boer N. K., Dijkstra G., West R., Moorsel S. A.W., et al.; of the Dutch Initiative on Crohn, Colitis (ICC). Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. Aliment Pharmacol Th er. 2019; 50(4): 407-415. PMID: 31359480 DOI: 10.1111/apt.15402.

Vasudevan A., Beswick L., Friedman A. B., Moltzen A., Haridy J., Raghunath A., et al. Low-dose thiopurine with allopurinol cotherapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. Dig Liver Dis. 2018;50(7):682-8. PMID: 29525182. DOI: 10.1016/j.dld.2018.02.001.

Vande Casteele N., Herfarth H., Katz J., Falck-Ytter Y., Singh S. American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel disease. Gastroenterology. 2017;153(3):835-57. PMID: 28774547. DOI: 10.1053/j.gastro.2017.07.031.

Mottet C., Schoepfer A. M., Juillerat P., Cosnes J., Froehlich F., Kessler-Brondolo V., et al. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(11):2733-47. PMID: 27760078. DOI: 10.1097/MIB.0000000000000923.

Khokhar O.S., Lewis J. H. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis. 2010;28(3):508. PMID: 20926880. DOI: 10.1159/000320410.

Ransford R.A., Langman M. J. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536-9. PMID: 12235076. DOI: 10.1136/gut.51.4.536.

Sehgal P., Colombel J. F., Aboubakr A., Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Th er. 2018;47(12):1597-609. PMID: 29722441. DOI: 10.1111/apt.14688.

FDA. Highlights of prescribing information: Delzicol. 2015. Available at: https://www.accessdata.fda.gov/drug-satfda_docs/label/2015204412s006lbl.pdf (accessed 7 February 2021)

Fisher M.C., Cronstein B. N. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009; 36: 539-545. PMID: 19208607. DOI: 10.3899/jrheum.080576.

Caliz R., del Amo J,. Balsa A., Blanco F., Silva L., Sanmarti R., et al. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol 2012; 41:10-14. PMID: 22044028. DOI: 10.3109/03009742.2011.617312.

Berends M.A., van Oijen M. G., Snoek J., et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol. 2007; 143: 1515-1519. PMID: 18087000. DOI: 10.1001/arch-derm.143.12.1515.

Khan N., Abbas A. M., Whang N., Balart L. A., Bazza-no L. A., Kelly T. N. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18: 359 367. PMID: 21751301. DOI: 10.1002/ibd.21820.

Tran-Minh M.L., Sousa P., Maillet M., Allez M., Gor-net J. M. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol. 2017;9(13):613-26. PMID: 28539989. DOI: 10.4254/wjh.v9.i13.613.

Saibeni S., Bollani S., Losco A., Michielan A., Sostegni R., Devani M., et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012 Feb;44(2):123-7. PMID: 22051323. DOI: 10.1016/j.dld.2011.09.015.

Labadie J.G., Jain M. Noninvasive tests to monitor for methotrexate-induced liver injury. Clinical Liver Disease 2019;13(3):67-71. PMID: 30988939. DOI: 10.1002/cld.765.

Laharie D., Seneschal J., Schaeverbeke T., Doutre M. S., LongyBoursier M., Pellegrin J. L., et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010; 53: 1035-1040. PMID: 20801541. DOI: 10.1016/j.jhep.2010.04.043.

Herfarth H.H., Kappelman M. D., Long M. D., Isaacs K. L. Use of methotrexate in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(1):224-33. PMID: 26457382. DOI: 10.1097/MIB.0000000000000589.

Drugs@FDA. FDA Approved Drug Products [Internet]. Available from: URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed 7 February 2021)

Bjornsson E.S., Gunnarsson B. I., Grondal G., Jonasson J. G., Einarsdottir R., Ludviksson B. R., et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2015; 13: 602-608. PMID: 25131534. DOI: 10.1016/j.cgh.2014.07.062.

Shelton E., Chaudrey K., Sauk J., Khalili H., Masia R., Nguyen D. D., et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Th er 2015; 41: 972-979. PMID: 25756190. DOI: 10.1111/apt.13159.

Koller T., Galambosova M., Filakovska S., Kubincova M., Hlavaty T., Toth J., et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol. 2017;23(22):4102-11. PMID: 28652663. DOI: 10.3748/wjg.v23.i22.4102.

Worland T., Chin K. L., van Langenberg D., Garg M., Nicoll A. Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study. Annals of Gastroenterology. 2020; 33(2):162-169. PMID: 32127737. DOI: 10.20524/aog.2020.0453.

Van den Brande J. M., Braat H., van den Brink G. R., Versteeg H. H., Bauer C. A., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-1785. PMID: 12806611. DOI: 10.1016/s0016-5085(03)00382-2.

Cantaert T., De Rycke L., Mavragani C. P., Wijbrandts C. A., Niewold T. B., Niers T., et al. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis 2009; 68: 1022-1029. PMID: 18625621. DOI: 10.1136/ard.2008.093724.

Gershov D., Kim S., Brot N., Elkon K. B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192: 1353-1364. PMID: 11067883. DOI: 10.1084/jem.192.9.1353.

Colina F., Molero A., Cas^s B., Martmez-Montiel P. Infliximab related hepatitis: a case study and literature review. Dig Dis Sci 2013; 58: 3362-3367. PMID: 23645381. DOI: 10.1007/s10620-013-2698-6.

Ghabril M., Bonkovsky H. L., Kum C., Davern T., Hayashi P. H., Kleiner D. E., et al. Liver injury from tumor necrosis factor-а antagonists: analysis of thirtyfour cases. Clin Gastroenterol Hepatol 2013; 11: 558-564.e3. PMID: 23333219. DOI: 10.1016/j.cgh.2012.12.025.

Ierardi E., Della Valle N., Nacchiero M. C., De Francesco V., Stoppino G., Panella C. Infliximab single administration followed by acute liver injury. Infl amm Bowel Dis 2006;12(11):1089-91. doi: 10.1097/01.mib.0000246783.75753.9f

Adar T., Mizrahi M., Pappo O., Scheiman-Elazary A., Shibolet O. Adalimumab-induced autoimmune hepatitis. J. Clin. Gastroenterol. 2010;44(1): e20-2. PMID: 19593165. DOI: 10.1097/MCG.0b013e3181a745e7.

Bezabeh S., Flowers C. M., Kortepeter C., Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010; 31: 1028-1035. PMID: 20163378. DOI: 10.1111/j.1365-2036.2010.04262.x.

Kornienko E. A. Vospalitel'nie zabolevaniya kishech-nika u detei [Inflammatory Bowel Disease in Children]. Moscow. Prima Print Publ., 2014. 208 p. (in Russian) Корниенко Е. А. Воспалительные заболевания кишечника у детей. М.: Прима Принт, 2014. 208 с.

Lisotti A., Azzaroli F., Brillanti S. Mazzella G. Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis. 2012;44(4):356-7. PMID: 22154948. DOI: 10.1016/j.dld.2011.11.003.

Lamb C.A., Kennedy N. A., Raine T., Hendy P. A., Smith P. J., Limdi J. K., et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68 (suppl 3): s1-s106. PMID: 31562236. DOI: 10.1136/gut-jnl-2019-318484.

FDA. Highlights of prescribing information: Entyvio (Vedolizumab). 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf. (accessed 7 February 2021)

Leonardi C.L., Kimball A. B., Papp K. A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. PMID: 18486739. DOI: 10.1016/S0140-6736(08)60725-4.

Leonardi C.L., Kimball A. B., Papp K. A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of usteki-numab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. PMID: 18486739. DOI: 10.1016/S0140-6736(08)60725-4.

Papp K.A., Langley R. G., Lebwohl M., Krueger G. G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. PMID: 18486740. DOI: 10.1016/S0140-6736(08)60726-6.

Llamas-Velasco M., Concha-Garzon M.J., Garda-Diez A., Dauden E. Liver Injury in Psoriasis Patients Receiving Ustekinumab: A Retrospective Study of 44 Patients Treated in the Clinical Practice Setting. Actas Dermosifi liogr 2015; 106: 470-476. PMID: 25912374. DOI: 10.1016/j.ad.2015.02.002.

Lovero R., Losurdo G., Mastromauro M., Castellane-ta N. M., Mongelli A., Gentile A., et al. A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal. Curr Drug Saf 2018;13(3):221-223. PMID: 30027852. doi: 10.2174/1574886313666180719165212.

Новиков П. И., Моисеев С. В. Ингибиторы янус-киназ: перспективы применения при ревматоидном и псориатическом артрите и других ревматических заболеваниях. Клиническая фармакология и терапия. 2020;4:41-47. DOI: 10.32756/0869-5490-20201-41-47.

Novikov P.I., Moiseev S. V. Janus kinase inhibitors: prospects for use in rheumatoid and psoriatic arthritis and other rheumatic diseases. Clinical pharmacology and therapy. 2020; 4: 41-47. (In Russ.) DOI: 10.32756/0869-5490-2020-1-41-47

Valenzuela F., Korman N. J., Bissonnette R., Bakos N., Tsai T. F., Harper M. K., et al. Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018;179(4):853-62. PMID: 29782642. DOI: 10.1111/bjd.16798.

Wollenhaupt J., Silverfield J., Lee E. B., Curtis J. R., Wood S. P., Soma K., et al. Safety and efficacy of Tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837-52. PMID: 24692527. DOI: 10.3899/jrheum.130683.

The authors declare that there are no conflicts of interest present.